Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Kulak AN, Grimes R, Kim YY, Semsarilar M, Anduix-Canto C, Cespedes O, Armes SP, Meldrum FC. Polymer-directed assembly of single crystal zinc oxide/magnetite nanocomposites under atmospheric and hydrothermal conditions. Chem Mater. 2016 Sep;28(20):7528-36. doi: 10.1021/acs.chemmater.6b03563
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Poole WK, Pollack M, Rapoport I, Williams V, Koch MA, Rao AV, Bartel DA. Use of Multivariate Methods in Quantifying the Variability in the Perception of Neonatal Intensive Care Unit Characteristics in Nine Hospitals in the Washington, DC Area: the NIH-DC Initiative to Reduce Infant Mortality in Minority Populations in the District of Columbia. Interstat. 2002 Jan 1.